Vascular protection to increase the safety of tissue plasminogen activator for stroke.

Current Pharmaceutical Design
Tauheed IshratSusan C Fagan

Abstract

Thrombolytic therapy with tissue plasminogen activator (tPA) remains the most effective treatment for acute ischemic stroke, but can cause vascular damage leading to edema formation and hemorrhagic transformation (HT). In this review, we discuss how tPA contributes to the pathogenesis of vascular damage and highlight evidence to support combination therapy of tPA with pharmacological agents that are vascular protective. There is an unmet need to develop therapeutic interventions which target the underlying mechanisms of vascular damage after acute ischemic stroke in order to prevent HT and improve the safety and impact of tPA.

Citations

May 26, 2015·Translational Stroke Research·Sahar SolimanSusan C Fagan
Nov 28, 2013·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Glen C JicklingFrank R Sharp
Mar 2, 2016·International Journal of Molecular Sciences·Hima Charika S AbeysingheCarli L Roulston
Dec 17, 2014·Stroke; a Journal of Cerebral Circulation·Cristina Merino-ZamoranoJoan Montaner
Jun 2, 2018·BioMed Research International·Ximing NieLiping Liu
May 10, 2018·Frontiers in Neurology·Xiao-Yi XiongQing-Wu Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.